Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases.
CONCLUSION: Overall efficacy of canakinumab was 93.1% in this study. No major adverse event was observed under canakinumab treatment. Canakinumab seems to be effective and safe in children with rheumatic diseases.
PMID: 32419407 [PubMed - in process]
Source: The Turkish Journal of Pediatrics - Category: Pediatrics Authors: Çakan M, Karadağ ŞG, Ayaz NA Tags: Turk J Pediatr Source Type: research
More News: Arthritis | Boys | Brain | Children | Colchicine | Colcrys | Girls | Neurology | Pediatrics | Pericarditis | Rheumatology | Study | Turkey Health